General MedicationsORALGeneric
ZMAX
AZITHROMYCIN
Standard Dose
EQ 2GM BASE/BOT
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ZMAX is listed in Drugs@FDA under application 050797 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient AZITHROMYCIN Form and strength FOR SUSPENSION, EXTENDED RELEASE;ORAL - EQ 2GM BASE/BOT Sponsor PF PRISM CV Submission history Latest submission status date: 2021-11-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZMAX is listed in Drugs@FDA under application 050797 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AZITHROMYCIN Form and strength FOR SUSPENSION, EXTENDED RELEASE;ORAL - EQ 2GM BASE/BOT Sponsor PF PRISM CV Submission history Latest submission status date: 2021-11-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.